Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017
This statistic depicts the share of insulin glargine sales attributable to Lantus compared to its biosimilar from 2015 to 2017. In 2015, Lantus held 100 percent of the insulin glargine sales in the United States. However, as of November 2017, Lantus held 81.1 percent of the market while biosimilar Basaglar held 18.9 percent of the market.
